Actively Recruiting
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Led by Shanghai Shengdi Pharmaceutical Co., Ltd · Updated on 2026-04-15
720
Participants Needed
1
Research Sites
163 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
CONDITIONS
Official Title
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participate in the study voluntarily and sign the informed consent form
- Able to provide primary or metastatic cancer samples
- Have at least one measurable lesion
- Expected survival greater than 3 months
- ECOG performance status of 0 to 1
- Have adequate organ functions
You will not qualify if you...
- Have distant metastatic disease confirmed by pathology or imaging, including lymph nodes above the first lumbar vertebra or in the inguinal region
- Received live vaccines within 4 weeks before enrollment or during planned treatment
- Received immunosuppressive therapy within 4 weeks before enrollment
- Have had other uncured malignant tumors in the past 5 years or currently, except cured basal cell carcinoma of the skin or carcinoma in situ
- Known allergy to the investigational drug or its ingredients, or severe allergic reaction to other monoclonal antibodies
- Are pregnant or breastfeeding
- Have any diseases or conditions that may seriously endanger safety, affect study results, or prevent study completion according to the investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
X
Xiaoxu Zhang
CONTACT
Z
Zhaoyu Zhong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here